App-Quantinova.ai

A novel non-canonical Notch-AKT- NF-B pathways in triple negative breast cancer cells

Fokhrul Hossain - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Everolimus

Targeting mTORC1 by overexpression of PRAS40(T246A) in basal keratinocytes suppresses proliferation and migration of keratinocyte stem cells and skin inflammation during tumor promotion

Okkyung Rho - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Identification of p62/SQSTM1 as a component of non-canonical WNT VANGL2-JNK signaling in breast cancer

Jean-Paul Borg - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

In-vitro growth inhibitory effects of diosmetin on human prostate cancer cells

Rebecca Pakradooni - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Rapacan

The influence of adipose tissue-derived mesenchymal stem cell environment and WNT antagonism on breast tumour cells

Malini Visweswaran - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The DNA strand breaking nucleoside analogue sapacitabine sensitizes Brca2-deficient ovarian cancer cells and synergizes with PARP inhibitors

Xiaojun Liu - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Decitabine

Novel dual HDAC & PI3K inhibitor, CUDC-907, for MYC-driven malignancies

Kaiming Sun - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

CUDC-907

Comparative cancer cell line profiling differentiates the mechanism of action of different PI3K/mTOR, Aurora kinase and EZH2 inhibitors

Joost C.M. Uitdehaag - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

EZH2

Chk1 inhibition: a promising targeted treatment for head and neck squamous cell carcinoma

Anne M. van Harten - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Reproductive hormone levels modulate doxorubicin induced cardiomyopathy in female tumor-bearing spontaneously hypertensive rats

Kaytee L. Pokrzywinski - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Doxorubicin

Doxorubicin induced cardiomyopathy associated with natural reproductive hormone cycling in female tumor-bearing spontaneously hypertensive rats

Kaytee L. Pokrzywinski - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

ADR-529

Cell cycle specific effects and associated DNA damage of selective inhibitors of nuclear export (SINE)

Russell T. Burke - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Selinexor

BET protein inhibition blocks growth of triple-negative breast cancer by inducing mitotic and cytokinetic dysfunction

Jennifer M. Brancato - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

AZD-1152

ODM-207, a novel BET-bromodomain inhibitor as a therapeutic approach for the treatment of prostate and breast cancer

Mari Bjorkman - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Enzalutamide

Combination Azacitidine and histone deacetylase inhibition induces a multi factorial synergistic anti-tumor response in non-small cell lung cancer (NSCLC)

Michael Topper - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Vidaza

Iron chelation inhibits mTORC1 signaling in tumor cells

Chaowei Shang - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Ciclopirox

Selective inhibitors epigenetically modify and eradicate tumor-initiating stem-like cells through downregulating microRNA 22-mediated TET induction and apoptosis

Chia-Lin Chen - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Vorinostat

Inhibition of p38 enhances ERK inhibitor efficacy in pancreatic ductal adenocarcinoma

Meagan B. Ryan - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

LY2228820

Targeting hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells

Fernanda Faiao-Flores - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Vemurafenib

A novel way to sensitize pancreatic cancer cells for gemcitabine treatment

Jingwu Xie - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Gemcitabine

Filters

41730 Abstracts